Regeneron Pharmaceuticals (REGN) has drawn investor attention after recent trading that leaves the stock down about 3% over the past month and roughly 18% over the past 3 months, despite positive trailing 1 year returns.

Against this backdrop, Regeneron Pharmaceuticals shows fading near term momentum, with the share price down about 20% year to date, yet a 1 year total shareholder return of roughly 19% still points to a stronger longer term picture.

If you are comparing Regeneron with other healthcare opportunities, it may be worth scanning a wider set of companies using our curated list of 38 healthcare AI stocks.

So with Regeneron Pharmaceuticals trading lower in recent months yet carrying analyst targets and intrinsic estimates above the current US$618 share price, is this a genuine value opportunity, or is the market already factoring in future growth?

Most Popular Narrative: 29.4% Undervalued

Regeneron Pharmaceuticals last closed at $618.03, while the most followed narrative places fair value at about $875, painting a very different picture from recent share price weakness.

Regeneron's broad and advancing pipeline, including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity, positions the company to benefit from demographic-driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline-driven earnings upside.

Want to see what sits behind that pipeline story and the fair value uplift it supports? The narrative leans heavily on projected revenue expansion, margin resilience, and a richer future earnings multiple, all pulled together under a specific discount rate that you will only see in the full breakdown.

Result: Fair Value of $875.31 (UNDERVALUED)

However, the Regeneron Pharmaceuticals story still carries real risk, with EYLEA competition and pricing pressure, as well as potential policy and reimbursement changes, capable of upsetting that undervaluation case.

Next Steps

With the Regeneron Pharmaceuticals narrative highlighting both upside and risk, now is a good time to review the data and make up your own mind. You can then weigh those potential upsides in more detail by checking the 4 key rewards

Looking for more investment ideas beyond Regeneron Pharmaceuticals?

Do not stop with Regeneron Pharmaceuticals. Use the Simply Wall Street Screener to spot fresh stock ideas that fit your style before the crowd gets there.

• Target potential bargains by scanning for companies that pair quality fundamentals with attractive pricing through the 44 high quality undervalued stocks.
• Strengthen your focus on balance sheet resilience by searching for companies highlighted in the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for opportunities that the market may be overlooking by reviewing the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.